Show simple item record

dc.contributor.authorMolero‑Luis, Marta
dc.contributor.authorCasas-Alba, Didac
dc.contributor.authorOrellana, Gabriela
dc.contributor.authorOrmazabal, Aida
dc.contributor.authorSierra, Cristina
dc.contributor.authorOliva, Clara
dc.contributor.authorValls, Anna
dc.contributor.authorVelasco, Jesus
dc.contributor.authorLaunes, Cristian
dc.contributor.authorCuadras, Daniel
dc.contributor.authorPérez‑Dueñas, Belén
dc.contributor.authorJordan, Iolanda
dc.contributor.authorCambra, Francisco J.
dc.contributor.authorOrtigoza‑Escobar, Juan D.
dc.contributor.authorMuñoz-Almagro, Carmen
dc.contributor.authorGarcia‑Cazorla, Angels
dc.contributor.authorArmangué, Thais
dc.contributor.authorArtuch, Rafael
dc.date.accessioned2021-02-11T17:39:02Z
dc.date.available2021-02-11T17:39:02Z
dc.date.issued2020
dc.identifier.citationMolero‑Luis, Marta; Casas‑Alba, Didac; Orellana, Gabriela [et al.]. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. Scientific Reports, 2020, 10, 18291. Disponible en: <https://www.nature.com/articles/s41598-020-75500-z>. Fecha de acceso: 11 feb. 2021. DOI: 10.1038/s41598-020-75500-zca
dc.identifier.issn2045-2322ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1984
dc.description.abstractThe elevation of neopterin in cerebrospinal fluid (CSF) has been reported in several neuroinflammatory disorders. However, it is not expected that neopterin alone can discriminate among different neuroinflammatory etiologies. We conducted an observational retrospective and case–control study to analyze the CSF biomarkers neopterin, total proteins, and leukocytes in a large cohort of pediatric patients with neuroinflammatory disorders. CSF samples from 277 subjects were included and classified into four groups: Viral meningoencephalitis, bacterial meningitis, acquired immune-mediated disorders, and patients with no-immune diseases (control group). CSF neopterin was analyzed with high-performance liquid chromatography. Microbiological diagnosis included bacterial CSF cultures and several specific real-time polymerase chain reactions. Molecular testing for multiple respiratory pathogens was also included. Antibodies against neuronal and glial proteins were tested. Canonical discriminant analysis of the three biomarkers was conducted to establish the best discriminant functions for the classification of the different clinical groups. Model validation was done by biomarker analyses in a new cohort of 95 pediatric patients. CSF neopterin displayed the highest values in the viral and bacterial infection groups. By applying canonical discriminant analysis, it was possible to classify the patients into the different groups. Validation analyses displayed good results for neuropediatric patients with no-immune diseases and for viral meningitis patients, followed by the other groups. This study provides initial evidence of a more efficient approach to promote the timely classification of patients with viral and bacterial infections and acquired autoimmune disorders. Through canonical equations, we have validated a new tool that aids in the early and differential diagnosis of these neuroinflammatory conditions.ca
dc.format.extent9ca
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.ispartofScientific Reportsca
dc.relation.ispartofseries10;
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.ca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.otherNeurologiaca
dc.subject.otherLíquid cefaloraquidi
dc.subject.otherInmunologia
dc.subject.otherNeurología
dc.subject.otherLíquido cefalorraquídeo
dc.subject.otherInmunología
dc.subject.otherNeurology
dc.subject.otherCerebrospinal fluid
dc.subject.otherImmunology
dc.titleCerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseasesca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.8ca
dc.identifier.doihttps://dx.doi.org/10.1038/s41598-020-75500-zca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/